major thalassemia. Thalassemia, unspecified
Conditions
Interventions
Intervention 1: In the intervention group previous treatment will be discontinued and patient will be treated with Defrosiroxe 20-40 mg/ kg/ day for one year. Intervention 2: The control group will be
Treatment - Drugs
In the intervention group previous treatment will be discontinued and patient will be treated with Defrosiroxe 20-40 mg/ kg/ day for one year
The control group will be treated with Deferoxamine 20-60 mg/ kg/ day in three doses with or without of Deferiprone 50-100 mg/ kg/ day in three doses
Sponsors
Research Center of Golestan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with major thalassemia with blood transfusions and treatment with Deferiprone with Deferoxamine; Ferritin levels below 5000ng/ml. Exclusion criteria:The patient dissatisfaction; drug intolerance.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum ferritin. Timepoint: Baseline, 3 month6month,9month,12month. Method of measurement: sampling and serum ferritin level(ng/ml).;Changes of MRI T2* normally, involves mild, moderate, severe. Timepoint: baseline, after one year. Method of measurement: MRI and The speed Back in phase T2* With millisecondand and classificate into four groups: normal, mild, moderate, severe. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhazal Vaseghi
Golestan University of Medical Sciences
Outcome results
None listed